<DOC>
	<DOCNO>NCT00744978</DOCNO>
	<brief_summary>1 . Assess efficacy varenicline , relative placebo , performance base measure cognition patient mild moderate Alzheimer 's disease 2 . Evaluate effect varenicline clinically relevant measure include attention executive function , behavior , clinician rat global change . 3 . Evaluate safety tolerability varenicline , relative placebo , patient mild moderate Alzheimer 's disease 4 . Evaluate pharmacokinetics varenicline patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Evaluation Efficacy Varenicline Cognition , Safety , Tolerability Pharmacokinetics Subjects With Mild-to-Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Males female , age 5585 Diagnosis probable Alzheimer 's disease , consistent criterion : 1 ) National Institute Neurological Communicable Disease Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) 2 ) Diagnostic Statistical Manual Mental Disorders ( DSM IV ) Minimental status exam score 1426 inclusive RosenModified Hachinski Ischemia Score &lt; = 4 Diagnosis history dementia neurodegenerative disorder Diagnosis history clinically significant cerebrovascular cardiovascular disease Subjects pulmonary disease evidence clinically significant pulmonary symptom</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>